TY - JOUR AU - Gadelha, Mônica R AU - Casagrande, Alessandra AU - Strasburger, Christian J AU - Bidlingmaier, Martin AU - Snyder, Peter J AU - Guitelman, Mirtha A AU - Boguszewski, Cesar L AU - Buchfelder, Michael AU - Shimon, Ilan AU - Raverot, Gerald AU - Tóth, Miklós AU - Mezősi, Emese AU - Doknic, Mirjana AU - Fan, Xiaolin AU - Clemmons, David AU - Trainer, Peter J AU - Struthers, R Scott AU - Krasner, Alan AU - Biller, Beverly M K TI - Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine. JF - JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM J2 - J CLIN ENDOCR METAB VL - 110 PY - 2025 IS - 1 SP - 228 EP - 237 PG - 10 SN - 0021-972X DO - 10.1210/clinem/dgae385 UR - https://m2.mtmt.hu/api/publication/34999595 ID - 34999595 N1 - Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study AB - Paltusotine is a nonpeptide selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly.To evaluate the efficacy and safety of paltusotine in the treatment of patients with acromegaly previously controlled with injected somatostatin receptor ligands (SRLs).This phase 3, randomized, double-blind, placebo-controlled trial enrolled adults with acromegaly who had insulin-like growth factor I (IGF-I) ≤1.0 times the upper limit of normal (×ULN) while receiving a stable dose of depot octreotide or lanreotide. Patients were switched from injected SRLs and randomized to receive paltusotine or placebo orally for 36 weeks. The primary endpoint was proportion of patients maintaining IGF-I ≤1.0×ULN. Secondary endpoints were change in IGF-I level, change in Acromegaly Symptom Diary (ASD) score, and maintenance of mean 5-sample growth hormone (GH) <1.0 ng/mL.The primary endpoint was met: 83.3% (25/30) of patients receiving paltusotine and 3.6% (1/28) receiving placebo maintained IGF-I ≤1.0×ULN (odds ratio: 126.53; 95% CI: 13.73, >999.99; P<.0001). Paltusotine was also superior to placebo for all secondary endpoints: mean (±SE) change in IGF-I of 0.04±0.09×ULN versus 0.83±0.1×ULN (P<.0001); mean (±SE) change in ASD score of -0.6±1.5 versus 4.6±1.6 (P=.02); mean GH maintained at <1.0 ng/mL in 20/23 (87.0%) versus 5/18 (27.8%) patients (odds ratio: 16.61; 95% CI: 2.86, 181.36; P=.0003). The most common adverse events were acromegaly symptoms and gastrointestinal effects characteristic of SRLs.Replacement of injected SRLs by once-daily oral paltusotine was effective in maintaining both biochemical and symptom control in patients with acromegaly and was well tolerated. LA - English DB - MTMT ER - TY - JOUR AU - Bényei, Erik AU - Remport, Ádám AU - Katonai, A AU - Tőke, Judit AU - Piros, László AU - Illés, Anett AU - Nagy, P AU - Kósa, János AU - Lakatos, Péter AU - Tóth, Miklós TI - MALIGNUS RENINOMA JF - MAGYAR BELORVOSI ARCHIVUM J2 - MBA VL - 77 PY - 2024 IS - 5-6 SP - 331 EP - 331 PG - 1 SN - 0133-5464 UR - https://m2.mtmt.hu/api/publication/35705583 ID - 35705583 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Bényei, Erik AU - Tőke, Judit AU - Huszty, Gergely AU - Borka, Katalin AU - Sápi, Zoltán AU - Jakab, Zsuzsanna AU - Kiss, Gergely AU - Kalina, Ildikó AU - Reismann, Péter AU - Uhlyarik, Andrea AU - Igaz, Péter AU - Tóth, Miklós TI - Clinical utility of S-GRAS prognostic system in adrenocortical carcinomas: confirmatory results from a single-centre institutional registry JF - ENDOCRINE ABSTRACTS J2 - ENDOCR ABSTR VL - 99 PY - 2024 SN - 1470-3947 DO - 10.1530/endoabs.99.EP254 UR - https://m2.mtmt.hu/api/publication/34863484 ID - 34863484 LA - English DB - MTMT ER - TY - JOUR AU - Gadelha, M AU - Randeva, H S AU - Gordon, M B AU - Doknic, M AU - Mezosi, E AU - Tóth, Miklós AU - Boguszewski, C L AU - Davidson, C AU - Ferrara-Cook, C T AU - Casagrande, A AU - Krasner, A TI - 12531 Long-term Safety And Efficacy Of Once-daily Oral Paltusotine In The Treatment Of Patients With Acromegaly: Update From Acrobat Advance JF - JOURNAL OF THE ENDOCRINE SOCIETY J2 - J ENDOCRINE SOC VL - 8 PY - 2024 IS - Supplement_1 SP - A661 EP - A662 SN - 2472-1972 DO - 10.1210/jendso/bvae163.1269 UR - https://m2.mtmt.hu/api/publication/35596775 ID - 35596775 AB - Disclosure: M. Gadelha: Consulting Fee; Self; Crinetics, Ipsen, Novo Nordisk, and Recordati. Grant Recipient; Self; Crinetics and Recordati. Speaker; Self; Ipsen, Novo Nordisk, and Recordati. H.S. Randeva: None. M.B. Gordon: Consulting Fee; Self; Crinetics Pharmaceuticals, HRA Pharma, Novo Nordisk, and Recordati Rare Diseases. Grant Recipient; Self; Ascendis, Camurus, Chiasma, Corcept, Crinetics, Ipsen, Novartis, Novo Nordisk, Opko, Pfizer, and Strongbridge. M. Doknic: Research Investigator; Self; Crinetics Pharmaceuticals. Speaker; Self; Merck, Novartis, Novo Nordisk, Pfizer, and Sandoz. E. Mezosi: Research Investigator; Self; Crinetics Pharmaceuticals. M. Toth: Consulting Fee; Self; Pfizer, Ipsen, Novo Nordisk, and Recordati. Research Investigator; Self; Crinetics Pharmaceuticals. Other; Self; Pfizer, Ipsen, Novo Nordisk, and Recordati. C.L. Boguszewski: Advisory Board Member; Self; Novo Nordisk and Recordati. Consulting Fee; Self; Ipsen, Novo Nordisk, and Recordati. Other; Self; Ipsen, Novo Nordisk, and Recordati. C. Davidson: Employee; Self; Crinetics Pharmaceuticals. C.T. Ferrara-Cook: Employee; Self; Crinetics Pharmaceuticals. A. Casagrande: Employee; Self; Crinetics Pharmaceuticals. A. Krasner: Employee; Self; Crinetics Pharmaceuticals.Paltusotine is a non-peptide, highly selective SST2 receptor agonist in development as a once-daily, oral treatment for patients with acromegaly or carcinoid syndrome. ACROBAT Advance is an ongoing, 6-year, single-arm, open-label extension study of paltusotine in the treatment of patients with acromegaly. Interim results as the first enrolled patients approach 4 years of treatment are reported here. Enrolled patients had completed either the ACROBAT Edge or Evolve phase 2 parent studies. In Edge, at enrollment all patients were candidates for combination drug therapy: either sub-optimally controlled on an injected SRL (octreotide or lanreotide) alone or in combination with cabergoline, or required combination therapy or pasireotide to achieve normal IGF-I levels. In Evolve, enrolled patients had normal IGF-I levels on injected SRL monotherapy. When the Advance study was initiated, paltusotine was formulated as a capsule (dose range, 10-40 mg); all patients were switched to the tablet formulation (dose range, 20-60 mg) during the third year of the study. As of this analysis, all patients had at least 2 assessments after switching to tablet formulation. Adjunctive treatment with cabergoline or pegvisomant was allowed in patients who did not attain normal IGF-I levels on the maximum dose of paltusotine. Forty-three patients were enrolled in Advance (Edge, n=32; Evolve, n=11; 88% of eligible patients): at baseline, mean (±SD) age 53.0±11.6 years, 56% female, 86% previous pituitary surgery, and none had prior radiotherapy. IGF-I control in Edge and Evolve subsets remained stable at parent study baseline values. For all patients pooled, median (IQR) IGF-I levels were 1.15× ULN (0.84, 1.46; n=43) at parent study baseline; in Advance, 1.14× ULN (0.89, 1.29; n=40), 1.06× ULN (0.87, 1.24; n=35), and 1.08× ULN (0.87, 1.57; n=10) at months 12, 24, and 42, respectively. As expected, patients receiving adjunctive medication during Advance largely derived from the Edge study. Acromegaly symptoms, as measured using the patient-reported Acromegaly Symptom Diary (score range, 0-70; higher values indicate greater symptom burden), were stably controlled: median (IQR) score of 8.6 (3.6, 20.1; n=21) at parent study baseline; in Advance, 10.5 (5.0, 18.5; n=40), 10.0 (5.0, 25.0; n=34), and 13.5 (6.0, 22.0; n=10) at months 12, 24, and 42, respectively. The most common AEs reported through month 42 were arthralgia (37.2%), headache (30.2%), and fatigue (23.3%). One serious drug-related AE (cholelithiasis) was reported. Of the 8 patients who discontinued the study, 2 were due to AEs (mild or moderate). Glycemic control, as measured by HbA1c, was stable during paltusotine treatment. In conclusion, long-term results show that once-daily oral paltusotine treatment was well tolerated, with stable biochemical and symptom control relative to that observed with injected SRLs. Support: Crinetics Pharmaceuticals.Presentation: 6/3/2024 LA - English DB - MTMT ER - TY - GEN AU - Gadelha, Monica R AU - Casagrande, Alessandra AU - Strasburger, Christian J AU - Bidlingmaier, Martin AU - Snyder, Peter AU - Guitelman, Mirtha A AU - Boguszewski, Cesar L AU - Buchfelder, Michael AU - Shimon, Ilan AU - Raverot, Gerald AU - Tóth, Miklós AU - Mezősi, Emese AU - Doknic, Mirjana AU - Fan, Xiaolin AU - Clemmons, David AU - Keeley, Michael AU - Trainer, Peter J AU - Struthers, R. Scott AU - Krasner, Alan AU - Biller, Beverly M.K. TI - ORAL PALTUSOTINE MAINTAINS IGF-I, GH, AND SYMPTOM CONTROL IN PATIENTS WITH ACROMEGALY SWITCHED FROM INJECTED SOMATOSTATIN RECEPTOR LIGAND MONOTHERAPY: THE PHASE 3, PATHFNDR-1 STUDY RESULTS. PY - 2024 UR - https://m2.mtmt.hu/api/publication/35596786 ID - 35596786 LA - English DB - MTMT ER - TY - JOUR AU - Isand, Kristina AU - Feelders, Richard AU - Brue, Thierry AU - Tóth, Miklós AU - Deutschbein, Timo AU - Reincke, Martin AU - Krsek, Michal AU - Santos, Alicia AU - Demtröder, Frank AU - Chabre, Olivier AU - Strasburger, Christian J AU - Aulinas Maso, Anna AU - Volke, Vallo AU - Pereira, Alberto M AU - Lohmann, Rüdiger AU - Gich Saladich, Ignasi AU - Webb, Susan M AU - Wass, John AU - Valassi, Elena ED - Amaral, C / Collaborator ED - Ambrogio, A / Collaborator ED - Aranda, G / Collaborator ED - Arosio, M / Collaborator ED - Balomenaki, M / Collaborator ED - Beck-Peccoz, P / Collaborator ED - Berr-Kirmair, C / Collaborator ED - Bertherat, J / Collaborator ED - Bolanowski, M / Collaborator ED - Bollerslev, J / Collaborator ED - Thierry, Brue / Collaborator ED - Cardoso, H / Collaborator ED - Carvalho, D / Collaborator ED - Cavagnini, F / Collaborator ED - Ceccato, P / Collaborator ED - Chabre, O / Collaborator ED - Chanson, P / Collaborator ED - Christ, E / Collaborator ED - Demtröder Zentrum Fur Endokrinologie, F / Collaborator ED - Denes, J / Collaborator ED - Deutschbein, T / Collaborator ED - Dimopoulou, C / Collaborator ED - Dreval, A / Collaborator ED - Droste, M / Collaborator ED - Duarte, J S / Collaborator ED - Dusek, T / Collaborator ED - Ertürk, E / Collaborator ED - Evang, J A / Collaborator ED - Fajardo, C / Collaborator ED - Fazel, J / Collaborator ED - Feelders, R A / Collaborator ED - Fica, S / Collaborator ED - García-Centeno, R / Collaborator ED - Ghigo, E / Collaborator ED - Goth, Miklós / Collaborator ED - Greenman, Y / Collaborator ED - Halperin, I / Collaborator ED - Hanzu, F A / Collaborator ED - Hermus, A / Collaborator ED - Johannsson, G / Collaborator ED - Hubina, E / Collaborator ED - Kamenicky, P / Collaborator ED - Kasperlik-Zaluska, A / Collaborator ED - Kirchner, J / Collaborator ED - Kastelan, D / Collaborator ED - Komerdus, I / Collaborator ED - Kraljevic, I / Collaborator ED - Krsek, M / Collaborator ED - Kruszynska, A / Collaborator ED - Lamas, C / Collaborator ED - Lambrescu, I / Collaborator ED - Lang, S / Collaborator ED - Luger, A / Collaborator ED - Maiter, D / Collaborator ED - Marpole, N / Collaborator ED - Martin, S / Collaborator ED - Martinie, M / Collaborator ED - Martins Oliveira, M J / Collaborator ED - Moros, O / Collaborator ED - Netea-Maier, R / Collaborator ED - Newell-Price, J / Collaborator ED - Orbetzova, M / Collaborator ED - Paiva, I / Collaborator ED - Pecori Giraldi, F / Collaborator ED - Percovich, J C / Collaborator ED - Pereira, A M / Collaborator ED - Pfeiffer, M / Collaborator ED - Pickel, J / Collaborator ED - Pirags, V / Collaborator ED - Ragnarsson, O / Collaborator ED - Reghina, A D / Collaborator ED - Reincke, M / Collaborator ED - Riesgo, P / Collaborator ED - Roberts, M / Collaborator ED - Roerink, S / Collaborator ED - Rowan, C / Collaborator ED - Rudenko, P / Collaborator ED - Sahnoun, M A / Collaborator ED - Salvador, J / Collaborator ED - Santos, A / Collaborator ED - Scaroni, C / Collaborator ED - Sigurjonsdottir, H A / Collaborator ED - Skoric Polovina, T / Collaborator ED - Smith, R / Collaborator ED - Stachowska, B / Collaborator ED - Stalla, G / Collaborator ED - Strasburger, C / Collaborator ED - Tabarin, A / Collaborator ED - Terzolo, M / Collaborator ED - Tőke, Judit / Collaborator ED - Tóth, Miklós / Collaborator ED - Touraine, P / Collaborator ED - Trainer, P J / Collaborator ED - Tsagarakis, S / Collaborator ED - Valassi, E / Collaborator ED - Vila, G / Collaborator ED - Vinay, S / Collaborator ED - Wagenmakers, M / Collaborator ED - Webb, S / Collaborator ED - Werner, S / Collaborator ED - Young, J / Collaborator ED - Zdunowski, P / Collaborator ED - Zacharieva, S / Collaborator ED - Zopf, K / Collaborator ED - Zopp, S / Collaborator ED - Zosin, I / Collaborator TI - High prevalence of venous thrombotic events in Cushing's syndrome. data from ERCUSYN and details in relation to surgery. TS - data from ERCUSYN and details in relation to surgery. JF - EUROPEAN JOURNAL OF ENDOCRINOLOGY J2 - EUR J ENDOCRINOL VL - 190 PY - 2024 IS - 1 SP - 75 EP - 85 PG - 11 SN - 0804-4643 DO - 10.1093/ejendo/lvad176 UR - https://m2.mtmt.hu/api/publication/34452033 ID - 34452033 N1 - Institute of Biomedicine and Translational Medicine, University of Tartu, Ülikooli 18, Tartu, 50090, Estonia Department of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC and Erasmus Cancer Institute, Rotterdam, 3015, Netherlands Aix Marseille Univ, APHM, INSERM, MMG, Department of Endocrinology Hospital La Conception, MarMaRa Institute, Marseille, 13305, France Department of Internal Medicine and Oncology, Semmelweis University, Budapest, 1083, Hungary Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, 97080, Germany Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, 80336, Germany Third Department of Internal Medicine, First Faculty of Medicine, Charles University, General University Hospital, Prague, 12808, Czech Republic IIB-Sant Pau, Department of Endocrinology, Hospital Sant Pau, Dept Medicine, UAB, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, Barcelona, 08025, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), Barcelona, Spain Zentrum fur Endokrinologie, Diabetologie, Rheumatologie, Dr Demtröder & Kollegen im MVZ Dr. Eberhard & Partner und Klinikum Dortmund, Dortmund, 44137, Germany University Grenoble Alpes, UMR 1292 INSERM-CEA-UGA, Endocrinologie CHU Grenoble Alpes, Grenoble, F-38000, France Clinical Endocrinology, Charite-Universitätsmedizin, Campus Mitte, Berlin, 10117, Germany Department of Endocrinology & Metabolism, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, 1081, Netherlands Health Care Consulting GmbH, Lohmann & Birkner Health Care Consulting GmbH, Berlin, 13407, Germany Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), Barcelona, 08025, Spain Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals, Oxford, OX37LE, United Kingdom Endocrinology and Nutrition Department, Germans Trias i Pujol Hospital and Research Institute, Badalona, 08916, Spain Centro Hospitalar do Porto-Hospital Santo António, Portugal Istituto Auxologico Italiano IRCCS, University of Milan, Milan, Italy Department of Endocrinology, Hospital Clinic Barcelona, IDIBAPS, UB, Barcelona, Spain Unit of Endocrine Diseases & Diabetology, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy Evangelismos Hospital, Athens, Greece Endocrinology and Diabetology Unit, Fondazione IRCCS Ca” Granda—Ospedale Maggiore Policlinico, University of Milan, Milan, Italy Hôpital Cochin, France Wroclaw Medical University, Wroclaw, Poland Section of Specialized Endocrinology, Oslo University Hospital, Faculty of Medicine, University in Oslo, Oslo, Norway Association pour le Devéloppement des Recherches Biologiques et Médicales, France Hospital de San Joao, Porto, Portugal Endocrinology Unit, University-Hospital of Padova, Italy Hospitalier Universitaire, Grenoble, France Univ Paris-Sud, Université Paris-Saclay UMR-S1185, Le Kremlin Bicêtre, Paris, F-94276, France Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service de Endocrinologie et des Maladies de la Reproduction, Le Kremlin Bicêtre, Paris, F-94275, France University Hospital of Bern, Inelspital, Division of Endocrinology, Diabetology and Clinical Nutrition, Bern, Switzerland Division of Endocrinology, 2nd Department of Medicine, State Health Center, Budapest, Hungary Medicover Oldenburg MVZ, Germany Max-Planck-Gessellschaft zur Forderung der Wissenschaften e.V., Munich, Germany Moscow Regional Research Clinical Institute n.a. Vladimirsky, Moscow, Russian Federation Praxis für Endokrinologie Droste, Oldenburg, Germany Serviço Endocrinologia CHLO, Hospital Egas Moniz, Portugal Department of Endocrinology, University Hospital Zagreb, School of Medicine University of Zagreb, Kispaticeva 12, Zagreb, 10000, Croatia Uludag University School of Medicine, Bursa, Turkey Hospital Universitario de la Ribera, Alzira, Spain Erasmus University Medical Centre, Rotterdam, Netherlands Elias Hospital, Bucharest, Romania Hospital General Universitario Gregorio Marañon, Spain Molinette Hospital, Department of Internal Medicine, Turin, Italy Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv, Israel Radboud University Medical Center, Nijmegen, Netherlands Goteborg University, Goteborg, Sweden Institut National de la Santé et de la Recherche Médicale U1185, Le Kremlin Bicêtre, Paris, F-94276, France Centre for Postgraduate Medical Education, Warsaw, Poland Division of Clinical Endocrinology, Department of Medicine CCM, Charité-Universitätsmedizin, Berlin, Germany Department of Endocrinology, University Hospital Zagreb, Kispaticeva 12, Zagreb, 10000, Croatia 2nd Department of Medicine, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic Endocrinology and Nutrition Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain Medizinische Universitat Wien, Wien, Austria UCL Cliniques Universitaires St Luc, Brussels, Belgium Christie Hospital, NHS Trust, Manchester, United Kingdom Service d'Endocrinologie-Diabétologie Nutrition, Grenoble, Cedex, France Centro Hospitalar Vila Nova Gaia/Espinho, Portugal Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands The University of Sheffield, Sheffield, United Kingdom Clinic of Endocrinology and Metabolic Diseases, “Sv. Georgy” University Hospital, Medical University, Plovdiv, Bulgaria Hospitais da Universidade de Coimbra, Portugal Leiden University Medical Center, Leiden, Netherlands Klinicni Center, Ljubljana, Slovenia Pauls Stradiņ š Clinical University Hospital, University of Latvia, Riga, Latvia Neurosurgery Department, Hospital Universitario de la Ribera, Alzira, Spain Estonian Endocrine Society, Tallinn, Estonia Aix-Marseille Université, CNRS, CRN2M UMR 7286, cedex 15, Marseille, 13344, France APHM, Hôpital Conception, Marseille, France University of Navarra, Pamplona, Spain IIB-Sant Pau, Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, Barcelona, Spain Landspitali University Hospital, Reykjavik, Iceland Faculty of Medicine, University of Iceland, Reykjavik, Iceland Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom Department of Endocrinology, Diabetology and Isotope Therapy Wroclaw Medical University, Wroclaw, Poland Department of Endocrinology, Diabetes and Nutrition, University of Bordeaux, Bordeaux, France Internal Medicine—Endocrinology, San Luigi Hospital, Italy 2nd Departement of Medicine, Semmelweis University, Budapest, Hungary GH Pitie Salpetriere, Dep. of Endocrinology and Repr. Med., France Department of Endocrinology, Christie Hospital, Manchester, United Kingdom Athens Polyclinic General Hospital, Evangelismos Hospital, Athens, Greece Department of Endocrinology, Hospital Germans Trias i Pujol, Badalona, Spain CIBERER Unit 747, ISCIII, Madrid, Spain Medical University of Sofia, Sofia, Bulgaria Romanian Society for Endocrinology, Timisoara, Romania Export Date: 30 January 2024 CODEN: EJOEE Correspondence Address: Isand, K.; Institute of Biomedicine and Translational Medicine, Ülikooli 18, Estonia; email: Kristina.iand@gmail.com Chemicals/CAS: hydrocortisone, 50-23-7; Hydrocortisone AB - The aim of this study was to evaluate the prevalence of venous thromboembolism (VTE) in patients included in the European Registry on Cushing's syndrome (ERCUSYN), compare their clinical characteristics with those who did not develop VTE and identify risk factors for VTE.A retrospective observational cohort study.Data extraction from the registry was taken on the 07.02.2022. At the time there were 2174 patients diagnosed with Cushing's syndrome (CS) and 95 VTE's reported in the database.Of 95 VTE events 70 (74%) were in pituitary-dependent CS patients, 12 (12.5%) in adrenal-dependant CS, 10 (10.5%) in ectopic CS and 3 (3%) in CS due to other causes.Sex, UFC value at diagnosis, as well as the number of operations remained statistically significant predictors of VTE.Of patients who were treated with at least one surgery, 12 (13%) VTE occured before and 80 (87%) after the surgery. Nearly half of these VTE's occurred within six months since the operation (36; 45%).Over half the centres who reported VTE did not routinely anticoagulate CS patients. Anticoagulation schemes varied widely.Patients with CS have elevated risk of developing VTE for an extended period of time. From ERCUSYN cohort patients have higher risk for VTE if they need multiple surgeries to treat CS, are males and have high UFC values at the diagnosis of CS.Since there is no agreement on thromboprohpylaxis, a protocol for VTE prevention which is widely adopted appears to be necessary in patients with CS. LA - English DB - MTMT ER - TY - JOUR AU - Kövesdi, Annamária AU - Tőke, Judit AU - Eitler, Katalin AU - Kiss, Gergely AU - Nyilas, Nóra Luca AU - Scheich, Bálint AU - Tóth, Miklós TI - A peculiar case of ectopic ACTH-syndrome - multiple challenges during diagnostic and therapeutic workup JF - ENDOCRINE ABSTRACTS J2 - ENDOCR ABSTR VL - 99 PY - 2024 SN - 1470-3947 DO - 10.1530/endoabs.99.P529 UR - https://m2.mtmt.hu/api/publication/35596764 ID - 35596764 LA - English DB - MTMT ER - TY - JOUR AU - Papp, E AU - Dénes, M AU - Zádori, A AU - Takó, K AU - Tóth, Miklós AU - Tőke, Judit AU - Szolnoky, J AU - Rácz, R. AU - Andréka, P TI - A karcinoid, amely nem válogat – a preoperatív echokardiográfia szerepe karcinoid szívbetegségben JF - CARDIOLOGIA HUNGARICA J2 - CARDIOL HUNG VL - 54 PY - 2024 IS - 6 SP - 439 EP - 443 PG - 5 SN - 0133-5596 DO - 10.26430/CHUNGARICA.2024.54.6.439 UR - https://m2.mtmt.hu/api/publication/35657439 ID - 35657439 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Perge, Pál AU - Mezei, P AU - József, I AU - Kiss, E AU - Huszty, Gergely AU - Kovács, K AU - Tőke, Judit AU - Tóth, Miklós TI - PRIMER BILATERALIS MACRONODULARIS MELLÉKVESE HYPERPLASIA JF - MAGYAR BELORVOSI ARCHIVUM J2 - MBA VL - 77 PY - 2024 IS - 5-6 SP - 354 EP - 354 PG - 1 SN - 0133-5464 UR - https://m2.mtmt.hu/api/publication/35711219 ID - 35711219 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Réti, Zsuzsanna AU - Tőke, Judit AU - Balla, Reka AU - Reismann, Péter AU - Kovács, Attila AU - Sápi, Zoltán AU - Bodor, Miklos AU - Nagy, Endre AU - Ivanyi, Gabor AU - Valkusz, Zsuzsanna AU - Mezosi, Emese AU - Tóth, Miklós TI - Diagnosis and therapy of medullary thyroid cancer. A real-life, retrospective, multicentric, Hungarian study JF - ENDOCRINE ABSTRACTS J2 - ENDOCR ABSTR VL - 99 PY - 2024 SN - 1470-3947 DO - 10.1530/endoabs.99.P372 UR - https://m2.mtmt.hu/api/publication/35596769 ID - 35596769 LA - English DB - MTMT ER -